专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09428557B2 Process for the production of biologically active HIV-1 tat protein 有权
标题翻译：用于生产生物活性HIV-1 tat蛋白的方法
公开(公告)号：US09428557B2
公开(公告)日：2016-08-30
申请号：US12866714
申请日：2009-02-06
申请人： Barbara Ensoli , Mauro Magnani
发明人： Barbara Ensoli , Mauro Magnani
IPC分类号： C12P21/02 , C07K14/15 , A61K35/00 , A61K39/21 , C07K14/155 , C07K14/16 , C07K14/005 , A61K38/16 , A61K39/00
CPC分类号： C07K14/163 , A61K38/162 , A61K39/00 , A61K39/21 , C07K14/005 , C07K14/15 , C07K14/155 , C07K14/16 , C07K2319/10 , C12N2740/16322
摘要： Tat protein produced in bulk culture is inactive when induced at conventional optical densities but can be obtained in biologically active form when induced during the logarithmic growth phase.
摘要翻译：在常规光密度下诱导时，在本体培养物中产生的Tat蛋白是无活性的，但是当在对数生长阶段中诱导时可以以生物活性形式获得。

2. 发明授权

US5990088A Method for treating kaposi's sarcoma with antisense oligonucleotides 失效
标题翻译：用反义寡核苷酸治疗卡波肉瘤的方法
公开(公告)号：US5990088A
公开(公告)日：1999-11-23
申请号：US463978
申请日：1995-06-05
申请人： Barbara Ensoli , Robert C. Gallo
发明人： Barbara Ensoli , Robert C. Gallo
IPC分类号： C12N15/09 , A61K31/70 , A61K48/00 , A61P35/02 , C07H21/04 , C07K14/50 , C12N15/113 , C12Q1/68 , C12N5/08
CPC分类号： A61K31/70 , C07K14/503 , C12N15/1136 , C12N2310/312 , C12N2310/315
摘要： The present invention relates to a method to treat Kaposi's sarcoma (KS), and particularly, human immunodeficiency virus associated KS through the administration of antisense oligonucleotides complementary to basic fibroblast growth factor RNA.
摘要翻译：本发明涉及通过施用与碱性成纤维细胞生长因子RNA互补的反义寡核苷酸来治疗卡波西氏肉瘤（KS），特别是与人类免疫缺陷病毒相关的KS。

3. 发明授权

US09969780B1 Tat complexes, and vaccines comprising them 有权
公开(公告)号：US09969780B1
公开(公告)日：2018-05-15
申请号：US10597926
申请日：2005-03-11
申请人： Barbara Ensoli
发明人： Barbara Ensoli
IPC分类号： C07K14/16 , A61K39/21 , A61K38/17 , C07K14/73
CPC分类号： C07K14/16 , A61K38/1774 , A61K39/00 , A61K39/12 , A61K39/21 , A61K2039/57 , A61K2039/622 , C07K14/005 , C07K14/162 , C07K14/163 , C07K14/70514 , C07K16/1063 , C07K16/1072 , C07K16/2866 , C12N2740/16122 , C12N2740/16134 , C12N2740/16322 , C12N2740/16334 , G01N2469/20
摘要： Complexes comprising HIV Tat and the V3 loop from gp120 Env provide novel epitopes and are immunogenic to prevent or inhibit infection by HIV.

4. 发明申请

US20060280798A1 Nanoparticles for delivery of a pharmacologically active agent 审中-公开
标题翻译：用于递送药理活性剂的纳米颗粒
公开(公告)号：US20060280798A1
公开(公告)日：2006-12-14
申请号：US10577973
申请日：2004-11-03
申请人： Barbara Ensoli
发明人： Barbara Ensoli
IPC分类号： A61K39/21 , A61K9/14
CPC分类号： A61K9/167 , A61K9/5052 , A61K48/00 , C12N15/88
摘要： Core-shell nanoparticles comprising: (a) a core which comprises a water insoluble polymer or copolymer, and (b) a shell which comprises a hydrophilic polymer or copolymer; said nanoparticles being obtainable by emulsion polymerization of a mixture comprising, in an aqueous solution, at least one water-insoluble styrenic, acrylic or methacrylic monomer and specific hydrophylic monomers or copolymers.
摘要翻译：核 - 壳纳米颗粒包含：（a）包含水不溶性聚合物或共聚物的芯，和（b）包含亲水性聚合物或共聚物的壳; 所述纳米颗粒可通过在水溶液中包含至少一种水不溶性苯乙烯，丙烯酸或甲基丙烯酸单体和特定亲水单体或共聚物的混合物的乳液聚合获得。

5. 发明申请

US20130058973A1 IMMUNE THERAPY 有权
标题翻译：免疫治疗
公开(公告)号：US20130058973A1
公开(公告)日：2013-03-07
申请号：US13636118
申请日：2011-03-21
申请人： Barbara Ensoli
发明人： Barbara Ensoli
IPC分类号： A61K39/21 , A61P31/04 , A61P37/04 , A61P33/02 , A61P31/10 , A61P31/18 , A61P31/12
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K39/21 , A61K2039/545 , A61K2039/57 , C07K14/163 , C12N2740/16311 , C12N2740/16322 , C12N2740/16334
摘要： Native Tat, when administered to patients with HIV infection, or who are otherwise immunocompromised, is capable of restoring immune functions so as to recognise recall antigens, and to inhibit replication and key signs of HIV disease and other persistent infections and/or their progression.
摘要翻译：天然Tat在给予HIV感染的患者或其他免疫受损的患者中能够恢复免疫功能，以便识别回忆抗原，并抑制HIV疾病和其他持续感染和/或其进展的复制和关键迹象。

6. 发明授权

US07811573B2 Compositions of antigens bound to HIV-1 Tat, fragments or derivatives thereof 失效
标题翻译：与HIV-1 Tat，其片段或衍生物结合的抗原组成
公开(公告)号：US07811573B2
公开(公告)日：2010-10-12
申请号：US10485180
申请日：2002-07-26
申请人： Barbara Ensoli
发明人： Barbara Ensoli
IPC分类号： A61K39/38 , A61K39/12 , A61K39/21 , A61K39/00 , A61K39/385
CPC分类号： C07K14/005 , A61K39/39 , A61K2039/5154 , A61K2039/53 , A61K2039/55516 , C12N2740/16322 , Y02A50/412
摘要： The present invention concerns a method for prophylactic and/or therapeutic vaccination and/or treatment and/or diagnosis of HIV/AIDS, other infectious diseases, inflammatory and angiogenic diseases and tumours which utilizes a biologically active HIV-1 Tat protein, fragments or derivates thereof, as a module with one or more of the following features: antigen, adjuvant and targeting-delivery system to specific antigen-presenting cells including dendritic cells, endothelial cells and macrophages. In particular, it is claimed that Tat can be used only in its biologically active form as an antigen combined with one or more other antigens, to prime or to boost protective immune responses against itself as well as other antigens and/or to selectively deliver these antigen(s) as well as active compounds to dendritic cells, endothelial cells and macrophages, due to its capability of targeting these A PC and of activating their maturation and functions and of increasing Th-1 type immune responses as an adjuvant. Therefore, due to these characteristics and to the distribution of these cells in the body (during physiological and pathological disorders), biologically active Tat, fragments or derivates thereof containing the RGD region, can be used for preventive, therapeutic and/or diagnostic purposes for HIV/AIDS, other infectious diseases, inflammatory and angiogenic diseases and tumors.
摘要翻译：本发明涉及一种用于预防和/或治疗预防和/或治疗和/或诊断艾滋病毒/艾滋病，其他感染性疾病，炎症和血管生成疾病和肿瘤的方法，其利用生物活性的HIV-1 Tat蛋白，片段或衍生物作为具有以下特征中的一个或多个的模块：抗原，佐剂和靶向递送系统到特定抗原呈递细胞，包括树突状细胞，内皮细胞和巨噬细胞。特别地，据称Tat可以仅以其生物活性形式用作与一种或多种其它抗原组合的抗原，以引发或增强针对其自身以及其他抗原的保护性免疫应答和/或选择性地递送这些抗原以及由树突状细胞，内皮细胞和巨噬细胞组成的活性化合物，由于其能够靶向这些A PC并激活其成熟和功能以及增加作为佐剂的Th-1型免疫应答。因此，由于这些特征和这些细胞在体内的分布（在生理和病理障碍期间），含有RGD区的生物活性的Tat，其片段或衍生物可用于预防，治疗和/或诊断目的艾滋病毒/艾滋病，其他传染病，炎症和血管生成疾病和肿瘤。

7. 发明申请

US20100015087A1 HIV-1 TAT, OR DERIVATIVES THEREOF FOR PROPHYLACTIC AND THERAPEUTIC VACCINATION 有权
标题翻译： HIV-1 TAT或其衍生物用于预防和治疗性疫苗
公开(公告)号：US20100015087A1
公开(公告)日：2010-01-21
申请号：US12436119
申请日：2009-05-06
申请人： BARBARA ENSOLI
发明人： BARBARA ENSOLI
IPC分类号： A61K39/21 , A61K38/20 , A61P31/18
CPC分类号： A61K39/21 , A61K38/00 , A61K39/00 , A61K39/12 , A61K2039/525 , A61K2039/53 , A61K2039/545 , A61K2039/55505 , A61K2039/55566 , C07K14/005 , C12N2710/16043 , C12N2740/16043 , C12N2740/16322 , C12N2740/16334
摘要： The present invention refers to Tat as the active principle for a prophylactic and/or therapeutic vaccine against HIV infection, the progression towards AIDS and the development of tumors and other syndromes and symptoms in subjects infected by HIV. Tat is in biologically active form either as recombinant protein or peptide or as DNA. More particularly, the invention refers to a vaccine based on HIV-1 Tat as immunogen, inoculated as DNA and/or recombinant protein or as peptides, alone or in combination with other genes or viral gene products (Nef, Rev, Gag) or parts thereof, or in combination with various immuno-modulant cytokines (IL-12, IL-15) or with the gene coding for an immuno-modulant cytokine or part thereof. Tat, Nef, Rev, Gag and the immuno-modulant cytokines are administrated both as a mixture of recombinant proteins, peptides or fusion proteins (Tat/Nef, Tat/Rev, Tat/Gag, Tat/IL-12, Tat/IL-15) or as plasmid DNA.
摘要翻译：本发明涉及Tat作为针对HIV感染的预防和/或治疗性疫苗的活性成分，艾滋病的进展以及感染HIV的受试者的肿瘤和其他综合征和症状的发展。 Tat作为重组蛋白或肽或DNA作为生物活性形式。更具体地，本发明涉及基于作为免疫原的HIV-1 Tat的疫苗，作为DNA和/或重组蛋白或作为肽单独接种或与其它基因或病毒基因产物（Nef，Rev，Gag）或部分或与各种免疫调节细胞因子（IL-12，IL-15）组合或与编码免疫调节性细胞因子或其部分的基因组合。 Tat，Nef，Rev，Gag和免疫调节细胞因子作为重组蛋白，肽或融合蛋白的混合物（Tat / Nef，Tat / Rev，Tat / Gag，Tat / IL-12，Tat / IL- 15）或作为质粒DNA。

8. 发明授权

US08926987B2 Replication-competent adenoviral vectors 有权
标题翻译：复制能力的腺病毒载体
公开(公告)号：US08926987B2
公开(公告)日：2015-01-06
申请号：US11282319
申请日：2005-11-17
申请人： Bo Peng , Rebecca Voltan , Barbara Ensoli , Marjorie Robert-Guroff
发明人： Bo Peng , Rebecca Voltan , Barbara Ensoli , Marjorie Robert-Guroff
IPC分类号： A61K39/12 , A61K39/23 , C12N15/86 , C07K14/005 , A61K39/00
CPC分类号： C12N15/86 , A61K39/21 , A61K2039/5256 , A61K2039/575 , C07K14/005 , C12N7/00 , C12N2710/10043 , C12N2710/10343 , C12N2710/16143 , C12N2740/15034 , C12N2740/15071 , C12N2740/16034 , C12N2740/16071 , C12N2740/16134 , C12N2740/16234 , C12N2740/16334
摘要： This invention provides improved replication-competent adenoviral vectors. The improved vectors have both a hybrid regulatory unit that provides for high level transgene expression. The vectors can be use, e.g., for therapeutic or prophylactic purposes.
摘要翻译：本发明提供了改进的复制能力的腺病毒载体。改进的载体具有提供高水平转基因表达的杂交调控单位。可以使用载体，例如用于治疗或预防目的。

9. 发明申请

US20110319593A1 PROCESS FOR THE PRODUCTION OF BIOLOGICALLY ACTIVE HIV-1 TAT PROTEIN 有权
标题翻译：生物活性HIV-1 TAT蛋白的生产工艺
公开(公告)号：US20110319593A1
公开(公告)日：2011-12-29
申请号：US12866714
申请日：2009-02-06
申请人： Barbara Ensoli , Mauro Magnani
发明人： Barbara Ensoli , Mauro Magnani
IPC分类号： C12P21/02 , C07K14/16
CPC分类号： C07K14/163 , A61K38/162 , A61K39/00 , A61K39/21 , C07K14/005 , C07K14/15 , C07K14/155 , C07K14/16 , C07K2319/10 , C12N2740/16322
摘要： Tat protein produced in bulk culture is inactive when induced at conventional optical densities but can be obtained in biologically active form when induced during the logarithmic growth phase.
摘要翻译：在常规光密度下诱导时，在本体培养物中产生的Tat蛋白是无活性的，但是当在对数生长阶段中诱导时可以以生物活性形式获得。

10. 发明申请

US20060115456A1 Replication-competent adenoviral vectors 有权
公开(公告)号：US20060115456A1
公开(公告)日：2006-06-01
申请号：US11282319
申请日：2005-11-17
申请人： Bo Peng , Rebecca Voltan , Barbara Ensoli , Marjorie Robert-Guroff
发明人： Bo Peng , Rebecca Voltan , Barbara Ensoli , Marjorie Robert-Guroff
IPC分类号： A61K48/00 , C12N15/861 , C12N15/867
CPC分类号： C12N15/86 , A61K39/21 , A61K2039/5256 , A61K2039/575 , C07K14/005 , C12N7/00 , C12N2710/10043 , C12N2710/10343 , C12N2710/16143 , C12N2740/15034 , C12N2740/15071 , C12N2740/16034 , C12N2740/16071 , C12N2740/16134 , C12N2740/16234 , C12N2740/16334
摘要： This invention provides improved replication-competent adenoviral vectors. The improved vectors have both a hybrid regulatory unit that provides for high level transgene expression. The vectors can be use, e.g., for therapeutic or prophylactic purposes.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式